Looking into the future: Gene and cell therapies for glaucoma

• Published in: Veterinary ophthalmology Vol. 24; no. S1; pp. 16 - 33
• Main Authors: Komáromy, András M., Koehl, Kristin L., Park, Shin Ae
• Format: Journal Article
• Language: English
• Published: England 01.03.2021
• Subjects: Animals; cell therapy; Cell- and Tissue-Based Therapy; gene therapy; Genetic Therapy; glaucoma; Glaucoma - therapy; Humans; intraocular pressure (IOP); neuroprotection; ocular biomechanics; ocular biomechanics; gene therapy; intraocular pressure (IOP); cell therapy; glaucoma; neuroprotection
• ISSN: 1463-5216; 1463-5224
• DOI: 10.1111/vop.12858

Glaucoma is a complex group of optic neuropathies that affects both humans and animals. Intraocular pressure (IOP) elevation is a major risk factor that results in the loss of retinal ganglion cells (RGCs) and their axons. Currently, lowering IOP by medical and surgical methods is the only approved treatment for primary glaucoma, but there is no cure, and vision loss often progresses despite therapy. Recent technologic advances provide us with a better understanding of disease mechanisms and risk factors; this will permit earlier diagnosis of glaucoma and initiation of therapy sooner and more effectively. Gene and cell therapies are well suited to target these mechanisms specifically with the potential to achieve a lasting therapeutic effect. Much progress has been made in laboratory settings to develop these novel therapies for the eye. Gene and cell therapies have already been translated into clinical application for some inherited retinal dystrophies and age‐related macular degeneration (AMD). Except for the intravitreal application of ciliary neurotrophic factor (CNTF) by encapsulated cell technology for RGC neuroprotection, there has been no other clinical translation of gene and cell therapies for glaucoma so far. Possible application of gene and cell therapies consists of long‐term IOP control via increased aqueous humor drainage, including inhibition of fibrosis following filtration surgery, RGC neuroprotection and neuroregeneration, modification of ocular biomechanics for improved IOP tolerance, and inhibition of inflammation and neovascularization to prevent the development of some forms of secondary glaucoma.